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Background
Anatomy of the CLL microenvironment
CLL cells recirculate between peripheral blood and tissue compartments, (i.e. the bone marrow and secondary lymphatic organs), where they proliferate in distinct tissue areas termed "proliferation centers" or "pseudofollicles".
Proliferation in these pseudofollicles accounts for a daily birth rate of approximately 1 -2 % of the entire clone, as determined by deuterated water labeling (1) . Studying the cross talk between CLL and tissue stromal cells led to the discovery of key mechanisms involved in CLL homing, proliferation, and survival, providing a rationale for therapeutic targeting of the CLL -stroma crosstalk ( Figure 1 and Table 1) .
Tissue stromal cells, such as stromal cells and monocyte-derived nurselike cells are critical elements of the tissue microenvironment in CLL, and the latter share lineage and function with lymphoma-associated macrophages described in other B cell malignancies. Mesenchymal stromal cells, such as bone marrow stromal cells, provide "feeder" layers for hematopoietic progenitor cells and are part of hematopoietic stem-cell niches in the normal bone marrow. They protect CLL cells from spontaneous and drug-induced apoptosis in a contactdependent fashion (2, 3) . These interactions not only take place in the marrow, mesenchymal stromal cells also are commonly found in secondary lymphatic tissues in CLL patients (4) , where they can provide survival and migration signals to CLL cells. In contrast, nurselike cells spontaneously develop in vitro from monocytes in CLL peripheral blood mononuclear cell cultures (5) , where they 4 form feeder layers and maintain CLL cell viability by activating numerous surface receptors and signaling pathways. Nurselike cells can be found in lymphoid organs from CLL patients (6, 7) , and gene expression profiles of CLL cells after co-culture with nurselike cells (8) are highly similar to those of CLL cells isolated from CLL lymph nodes (9), suggesting that nurselike cells are a highly relevant model system for studying the microenvironment.
Stromal cells constitutively secrete chemokines which organize CLL cell trafficking and tissue homing (10) and provide additional signals that support survival and growth and protect CLL cells from drug-induced apoptosis. Not only CLL cells benefit from bone marrow stroma contact, the stromal cells in turn also become activated by the CLL cells, with induction of protein kinase C (PKC)-βII expression and subsequent NF-κB pathway activation (11). In vivo, nurselike cells are found in lymphoid organs from CLL patients (6) and activate prosurvival signaling pathways in CLL cells (8) . Nurselike cells attract and protect leukemic CLL cells through secretion of chemokines (CXCL12 (5) and CXCL13 (7)), support their survival via expression of the TNF family members BAFF and APRIL (12), and promote CLL disease progression, as demonstrated in recent CLL animal models (13, 14) . The similarity between nurselike cells -induced gene expression profiles (GEP) in CLL cells (8) and GEP of CLL cells isolated from lymphatic tissues (9) suggests that nurselike cells are a valid and probably the best model system to imitate the in vivo microenvironment.
T and NK cells
Research. (18) . NK-cell mediated antitumor activity is also limited, as NK cells from CLL patients express low levels of the activating receptor NKp30 (19, 20) and show reduced cytotoxicity in response to soluble BAG6 ligand produced by CLL cells (19) . Taken together, it is evident that CLL cells actively shape an immune-protected environment, where the leukemia cells can escape immunemediated destruction. VLA-4 integrins cooperate with chemokine receptors and CD38 (26) in CLL cell adhesion to stromal cells (27) . In addition, high CD38 (28) Author Manuscript Published OnlineFirst on December 9, 2013; DOI: 10.1158/1078-0432.CCR- In addition, the BCR signaling is modulated by receptor endocytosis, signaling of positive (e.g. CD19) and negative (e.g. CD5, CD22) regulatory coreceptors, intracellular kinases (e.g. SYK, BTK and PI3K) and phosphatases, (e.g. FcβRIIIb, SHIP, SHP-1 and PTPN22 (42) 
Clinical-translational advances
The current standard of care for younger patients with CLL is chemoimmunotherapy, and one of the most commonly used regimens is FCR Ibrutinib also reduces tumor burden in mouse models of human CLL (56, 58) .
The results of a phase 1b-2 multicenter study conducted on 85 patients have recently been published and show high rates of durable remissions in patients with relapsed or refractory CLL, including patients with high-risk genetic lesions (52) . Early lymphocytosis and organomegaly reduction was observed, followed by lymphocyte count normalization, which occurred more frequently and more rapidly in patients carrying unmutated IGHV genes. The estimated progressionfree survival rate was 75% at 26 months, with an overall survival rate of 83%.
Ibrutinib is currently explored in combination with either chemotherapy or monoclonal antibodies to shorten lymphocytosis and to increase complete remission rates (59) . Whether higher response rates translate into longer progression-free survival will be critical for further development of combination strategies. SYK and rapidly converts in vivo into the bioactive form called R406 (63) . R406 inhibits CLL cell migration, chemokine secretion and BCR signaling (64) and inhibits tumor growth in a CLL mouse model (65) . On the clinical side, partial responses in a number of relapsed CLL patients were reported in phase I/II study (66) , but further development of this drug focused on rheumatoid arthritis (67) .
PI3Ks are divided into 3 classes (I through III) and class I is further
Additional SYK-specific inhibitors are under development and preclinical testing, showing effective inhibition of CLL cell survival and response to microenvironmental cues (68) .
Targeting the CXCR4-CXCL12 axis
The CXCR4-CXCL12 axis is an attractive therapeutic target, based on the 
plerixafor, and a plerixafor dose-dependent mobilization of CLL cells from the tissues into the blood was reported (73) . Given the robust and sustained mobilizing effects of BCR kinase inhibitors (BTK, PI3Kδ, SYK inhibitors) (52, 62) it is unclear in which setting the more specific CXCR4 or CXCL12 antagonists may have advantages.
Conclusions and perspective
A plethora of cellular and molecular players in the CLL microenvironment promote the survival and evolution of CLL leukemic cells. Over the past few years, the clinical success of kinase inhibitors targeting BCR-associated kinases put the spotlight on the CLL microenvironment. The rapid translational development of these agents, along with basic discoveries, identified BCR signaling as a central patho-mechanism, and BCR-related novel biomarkers that predict disease progression and response to therapy with these novel agents. Tissue retention of CLL cells [2] ; CLL cells drug resistance [2] and protection from apoptosis [2] ; PKC-βII activation in BMSCs induced by CLL cells [4] Nurselike cells (NLC)
Not applicable Tissue retention of CLL cells [3] ; CLL cells drug resistance [3] and protection from apoptosis [3] ; CLL cell attraction by CXCL12 and CXCL13 production [3] ; BAFF and APRIL expression [11]; activation of BCR and NF-kB pathway genes in CLL cells [8] ; disease progression in vivo [6, 7] ; interaction with CD38-expressing cells via CD31 [14] .
CD4 + T cells/ T helper cells
Adaptive immune responses; antigen recognition; T-APC immune synapse formation; APC activation via CD40/CD40L interaction. [24] ; defective immune synapse formation upon contact with CLL cells [26, 28] ; CD40L + CD4 + T cells induce CLL cells to produce CCL17 and CCL22 [20, 21] Reduced cytotoxicity [28] ; low expression of NKp30 activating receptor [29] Research.
CLL engraftment in vivo
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